How do angiotensin receptor blockers (ARBs) compare with angiotensin-converting enzyme inhibitors (ACEIs) for people with primary hypertension?

Moderate‐ to low‐certainty evidence suggests no differences in all‐cause mortality or cardiovascular mortality or morbidity during a mean follow‐up period up to 4.5 years between people taking angiotensin receptor blockers and those taking angiotensin‐converting enzyme inhibitors for primary hypertension

Bipin Thapa


Scholarcy highlights

Need more features? Save interactive summary cards to your Scholarcy Library.